tend to disagree GD..I don't feel that costs have sky rocketed..I'll try and explain my view..whilst ignoring the placement implications
...net operating cash flow NOCF) this quarter worsened by around $1.5M over the previous quarter
.....part of that was due to less cash being received approx $400K compared too the previous quarter (one might have expected more but this is only a timing issue) as we know revenue for the period was $2.5M of which CardioCel contributed $1M, so another $600k+ in cash is still to flow in (this excludes any cash which may be owing for longer than three months)..these $$$ are coming...
....throw in around an additional $850K in working capital increasing the balance of stocks of CardioCel (which is also an asset of the company that will be sold at a much higher price)...this was obviously needed to meet future demand for CardioCel...this is not wasted $$$
...R&D has increased by $150K compared to the previous quarter ..needed I would assume..this costs is fully recoverable...this is not wasted $$$
...that leaves staff costs which increased by $202K over the quarter....a break up of this mayhelp...these may or not be wasted $$$ but no-one here can determine this
..imo, the claim that costs have sky rocketed falls short , but happy to be picked apart..
AHZ Price at posting:
7.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)